Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-089 long-term safety in adults with ADHD
NCT00443391Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pozanicline in attention deficit hyperactivity disorder (ADHD), sponsored by AbbVie Inc. Primary endpoints: Conners' Adult ADHD Rating Scales: Investigator Rated and Clinical Global Impression - ADHD - Severity. Started Feb 2007; status: completed.
02
Drugs
pozanicline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00443391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443391.